Blog Layout

📖 Headache in long COVID as disabling condition: A clinical approach

Rodrigues et al / Frontiers in Neurology • 23 March 2023

❦ The major late neurological manifestations [of Long COVID syndrome] include hyposmia, hypogeusia, dizziness, insomnia, and headache characterized by intense and frequent chronic pain that is resistant to easily accessible drugs.

Headache is a disabling condition in patients with Long COVID-19, exacerbating the conditions of those with headaches prior to contracting COVID-19.

❂

📖 (23 Mar 2023 ~ Frontiers in Neurology) Headache in long COVID as disabling condition: A clinical approach ➤

C-19: Archives

✾ Useful Search tags

airborne / air filtration / babies & children / body / brain / C19.Life / cancer / comment / COSHH / dementia / economy / elders / excess deaths / exercise / flu / healthcare workers (HCW) / heart / HEPA / history / HIV / hospitals / immunity / influenza / Lisa Iannattone / long covid / lungs / lymphopenia / mitochondria / muscles / musculoskeletal / NHS / NHS estates / Noor Bari / nosocomial / PEM / parkinson’s / propaganda / public health / reinfections / reproduction and pregnancy / resources / respirators / respiratory / risk / SARS(-CoV-1) / schools / Semmelweis / solutions / transmission / UKHSA / universities / UVC / vaccines / variants / WHO / young adults / zoonosis

All Archives

A raven’s overview

by Zdeněk Vrožin MBA • 25 January 2026

‘Prevention wasn’t impossible. It was withheld. In people with pre-existing dementia, SARS-CoV-2 infection is repeatedly associated with faster cognitive decline. For families, that can mean the difference between years at home and a rapid fall over months.’

✾ On SARS-CoV-2 (COVID-19), brain damage, neurological damage, and dementia

by C19.Life... et al • 21 November 2025

‘Although COVID-19 was originally considered a respiratory illness, it is now well established that SARS-CoV-2 infection can have far-reaching impacts on the nervous system. Common neurological symptoms in Long COVID [PASC] include new-onset cognitive difficulties, dysautonomia, fatigue, and peripheral neuropathy.’ from ‘Neuroimmune pathophysiology of long COVID’ by Moen et al / Psychiatry and Clinical Neurosciences (2025).

📖 Neurological and neurodevelopmental effects of Covid and MIS-C on children

by Byrne et al ~ Nature Pediatric Research / Bioengineer • 11 November 2025

‘The pediatric population, once thought to be relatively spared from severe outcomes, has presented with significant neurological manifestations that raise concerns about the short- and long-term effects of SARS-CoV-2 on the developing nervous system.’

Knock-knock... It’s mild!

by C19.Life • 5 November 2025

“How mild can a cigarette be?”

A WHO’s Who of VOCs, VOIs and VUMs: Alphabet Stew and Numeric Ragout for Dummies

by C19.Life • 1 November 2025

“We’re going to need a bigger Greek alphabet.”

'The Approved List of biological agents'. Advisory Committee on Dangerous Pathogens / UKHSA.

On Biosafety Levels, Hazard Groups, SARS-CoV-2, the UKHSA, Notifiable Organisms and Notifiable Diseases

by United Kingdom Health Security Agency (UKHSA) / Health & Safety Executive (HSE) / Control of Substances Hazardous to Health Regulations (COSHH) / C19.Life • 23 October 2025

The Health and Safety Executive (HSE) has designated SARS-CoV-2, the virus that causes COVID-19, a Hazard Group 3 (HG3) pathogen that can cause severe human disease. The United Kingdom’s Health Security Agency (UKHSA) classifies SARS-CoV-2 as a notifiable organism, and COVID-19 as a notifiable disease (2025).

📖 Guidance for Healthcare Employers and Workers on the use of Fluid Resistant Surgical Masks (FRSM) and respirators (FFP3 etc) to comply with the requirements of COSHH (2002) (England) (Updated 2025)

by The British Occupational Hygiene Society ~ COSHH and Healthcare Respiratory Protection • 20 October 2025

‘FRSMs [Surgical Masks] have never been considered either adequate or suitable equipment for protection against inhalable or respirable risks under COSHH.’

Show More Articles

❦ postscript

You are free to disagree with anything you read here, provided that you have an authentic, evidence-based argument for it.

❦ All content on this website is for informational and educational purposes only.

Create your business website with

Website Builder.

Share by: